Guido Cavaletti

Full Professor

MD
+39 02 6448 8039
guido.cavaletti@unimib.it
Guido Cavaletti

Curriculum Vitae

SCOPUS Author ID:  7004360275, ORCID ID:  0000-0003-4128-2406

 

EDUCATION: MD, Board in Neurology.

 

POSITIONS

  • Professor of Human Anatomy, University of Milano-Bicocca, Monza.
  • Senior consultant neurologist and head of the Neuroimmunology Center, San Gerardo dei Tintori Foundation for Clinical Care and Research (IRCCS), Monza (Italy).
  • Head of the Experimental Neurology Unit at the School of Medicine and Surgery and former Director of the PhD program in Neuroscience, University of Milano-Bicocca, Monza.
  • Member of the Board of Directors of the Peripheral Nerve Society as Chair of the Toxic Neuropathy Consortium.
  • Vice Rector for Research at the University of Milano-Bicocca.
  • Coordinator of the steering committee of the international CI-PeriNoms group on the investigation of chemotherapy-induced peripheral neurotoxicity.
  • Member of the Board of Directors of the Foundation for Clinical Care and Research (IRCCS), Monza

 

PUBLICATIONS

Author of more than 350 peer-reviewed papers (Scopus h-index = 71, > 17,000 citations).

 

SELECTED INVITED LECTURES AND SCIENTIFIC ADVISORY BOARDS

Besides several International meetings, invited lectures or advisory board invitations at meetings organized by the US National Cancer Institute, National Institute of Health, Food and Drug Administration, American Society for Clinical Oncology, American Academy of Neurology, European Neurology Society/European Federation of Neurological Societies (currently European Academy of Neurology), European Association for Clinical Oncology, and International Association for the Study of Pain.

 

AWARD

Alan J Gebhart Prize for Excellence in Peripheral Nerve Research for 2020, provided by the International Peripheral Nerve Society (Baltimore, MD)

 

RESEARCH INTERESTS

  • Preclinical and clinical assessment of chemotherapy-induced peripheral neurotoxicity (CIPN)
  • Preclinical and clinical assessment of diabetic neuropathy
  • Experimental autoimmune encephalomyelitis and multiple sclerosis
  • Use of mesenchimal stem cells in models of neurological diseases
  • Biological effects of synchrotron radiation and X ray-based imaging

 

CIPN RESEARCH ACTIVITIES

The preclinical research activities in the investigation of CIPN are focused on the study of its pathogenesis and on its characterization in proper models. The experimental approaches include mechanistic studies in vitro based on primary (neuronal, glial) and organotypic (dorsal root ganglia) rodent cultures, IPS-derived human sensory neurons and human primary sensory neuron culture, as well as the implementation of in vivo mice/rat CIPN models. Behavioral, neurophysiological and pathological methods currently available at the ENU will be used in the in vivo studies.

The clinical investigation of CIPN is primarily performed at the San Gerardo dei Tintori Foundation for Clinical Care and Research (IRCCS) in Monza, and deals with adult outpatients assessment in close collaboration with the Oncology Department. A new collaboration has recently been established with the Pediatric Hematology Department to investigate the effect of vincristine in children affected by leukemias.

Upon specific agreements, partnership with Industries can be enforced to develop common research projects.

 

MOST RECENT GRANTS

  • 2023 – ongoing: AdvaNced Technologies for Human-centrEd Medicine (ANTHEM) – MINISTERO DELL’UNIVERSITA’ E DELLA RICERCA (PI)
  • 2021 – ongoing: HDACi: the Columbus’s egg in improving cancer treatment and reducing neurotoxicity?- FONDAZIONE AIRC PER LA RICERCA SUL CANCRO (PI)
  • 2020 – ongoing: NanoCosPha – Infrastruttura Regionale Lombarda – Nanotecnologie per la medicina personalizzata e i trattamenti di salute e cura estetica – REGIONE LOMBARDIA (PI)
  • 2019 – 2022: IMMUN-HUB – Sviluppo di nuove molecole di seconda generazione per immunoterapia oncologica – REGIONE LOMBARDIA (local PI)
  • 2018 – ongoing: Identificazione di polimorfismi genici e alterazioni epigenetiche per lo sviluppo di nuovi approcci farmacologici nel trattamento della neuropatia da oxaliplatino in pazienti con carcinoma colorettale – AGENZIA REGIONALE DI SANITA’ DELLA TOSCANA (local PI)
  • 2018 – ongoing: Mechanisms of anti-tubulin activity of anticancer drugs and their relevance to neurotoxicity – THOMPSON FOUNDATION AT COLUMBIA UNIVERSITY OF NEW YORK (co-PI)
  • 2017 – 2023: Pathogenesis of Chemotherapy-Induced Peripheral Neurotoxicity (Pa-CIPN) – – MINISTERO DELL’UNIVERSITA’ E DELLA RICERCA (PI)
  • 2016 – 2018: Radiation-enhanced metal-based chemotherapy in the treatment of solid tumors – FONDAZIONE AIRC PER LA RICERCA SUL CANCRO (PI)

 

EDITORIAL ACTIVITY

– Associate Editor, Journal of the Peripheral Nervous System (John Wiley & Sons)

– Editorial Board Member of Experimental Neurology (Elsevier), Current Medicinal Chemistry (Bentham Science), Current Drugs Safety (Bentham Science), Toxics (MDPI)

 

MAIN FOREIGN ACADEMIC COLLABORATIONS

  • A. Hoke and D. Cornblath, Johns Hopkins University, Baltimore (MD)
  • F. Bartolini, Dr. F Lotti, Columbia University, New York (NY)
  • A. Sparreboom, Ohio State University, Columbus (OH)
  • S. Dorsey, University of Maryland, Baltimore (MD)
  • J.S. Gewandter, University of Rochester, Rochester (NY)
  • S. Park, University of Sidney, Sydney, (Australia)
  • E. Smith, University of Alabama, Birmingham (AL)
  • A. Argyriou, Patras University Hospital, Patras (Greece)
  • J Bruna, Universitat de Barcelona (Spain)

 

MAIN INDUSTRIAL COLLABORATIONS

AlgoTx, Augustine Tx, Grunenthal, Helsinn, Italfarmaco, Johnson & Johnson, Kedrion, Kyowa, Merck & CO, Metys, Mundipharma, Nitto, Novartis, NuraBio, Pledpharma, Pfizer, Roche, UCB

 

PATENTS

  • DELTA-2-TUBULIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR PERIPHERAL NEUROPATHY – WO2019108835A1 • 2019-06-06 • UNIV COLUMBIA [US]
  • METHODS AND MATERIALS FOR TREATING NEUROTOXICITY WO2021067697A1 • 2021-04-08 • CAVION INC [US]